



Pricing & New Medicines Committee 2012-2015

Nikos Kefalas
Vice President SFEE

March 20th, 2015

Athens

Key achievements (1/2)

- Substantial development in the pricing process, in respect to transparency and prediction (3 price bulletins with NEW drugs in 2014!)
- Legislation that supports the patent use and not data protection use for the definition of off-patent.
- Finalisation of SFEE pricing proposal
- Corrections of prices being at the EU lowest price
- Predictability for the introduction of new products

Key achievements (2/2)

- Strong presence in MoH Price Committee
- Continuous and close monitoring of developments in pricing periods and changes of legislation
- Build close and trusted collaboration with several meetings at EOF and MoH for pricing issues and submission of proposals and letters
- Several committee meetings within SfEE for alignment / update / exchange ideas / shape arguments

Developments/Outlook 2015

- Imminent repricing expected in April 2015
- Pending price approvals for new drugs (since 10/2014)
- Discussion on new pricing system and possible changes, according to the average of 3 lowest in Eurozone
- Possible differentiation of actual reimbursement price
- SFEE play important role as contributor in discussions with MoH and submit proposals in alignment with PEF and SAFEE.
- Support local manufacturing